Skip to main content

Byooviz News

Updated FDA Labeling Recommendations for Biosimilar and Interchangeable Biosimilar Products

October 26, 2023 – Over the last eight years, FDA has approved more than 40 biosimilar products (biosimilars), and they have become an important treatment option for health care professionals and...

Dexamethasone Best for Persistent, Recurrent Uveitic Macular Edema

THURSDAY, June 22, 2023 – For patients with minimally active or inactive uveitis and persistent or recurrent uveitic macular edema (ME), dexamethasone is significantly better for treatment than...

FDA Approves Byooviz (ranibizumab-nuna), a Biosimilar to Lucentis

INCHEON, Korea and CAMBRIDGE, Mass. – September 20, 2021 – Samsung Bioepis Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has approved Byo...

Ask a question

To post your own question to this support group, sign in or create an account.

Further information

Related condition support groups

Macular Degeneration

Byooviz patient information at Drugs.com